Company Filing History:
Years Active: 2013
Title: Frank Dininno: Innovator in Beta-Lactamase Inhibition
Introduction
Frank Dininno is a notable inventor based in Barnegat, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for beta-lactamase enzymes. His work is crucial in enhancing the effectiveness of beta-lactam antibiotics against resistant microorganisms.
Latest Patents
Frank Dininno holds 1 patent for his invention titled "Inhibitors of beta-lactamase." This invention provides novel β-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class. These compounds contain nitrogen-based cations or quaternary ammonium groups, which inhibit three classes of β-lactamases. This innovation synergizes the antibacterial effects of β-lactam antibiotics, such as imipenem and ceftazidime, against microorganisms that are typically resistant due to the presence of β-lactamases.
Career Highlights
Frank Dininno is associated with Methylgene, Inc., where he continues to advance his research and development efforts. His work has been instrumental in addressing the challenges posed by antibiotic resistance, making significant strides in the pharmaceutical industry.
Collaborations
Some of his notable coworkers include Milton L Hammond and Kevin D Dykstra. Their collaborative efforts contribute to the innovative environment at Methylgene, Inc., fostering advancements in antibiotic therapies.
Conclusion
Frank Dininno's contributions to the field of beta-lactamase inhibition highlight the importance of innovation in combating antibiotic resistance. His work not only enhances the efficacy of existing antibiotics but also paves the way for future developments in pharmaceutical research.